IBB holdings - what the fund actually owns
iShares Biotechnology ETF reports 238 stock positions to the SEC, 100% of its assets. The ten largest are 44.7% of the fund, as of Jun 30, 2026.
Each week Ploutos reads the latest N-PORT filing of the largest US equity ETFs. This page is one fund's filing: its reported positions with their weights, where that weight sits by sector, what entered and left since the previous filing, and which other funds hold the most of the same stocks.
Reported positions
238
cover 100% of the fund
Weight of the top 10 holdings
44.7%
of the fund in ten names
Largest position
VRTX
8.08% · Vertex Pharmaceuticals, Inc.
Filing date
Jun 30, 2026
holdings as reported to the SEC
Where the weight sits, by sector
Healthcare
97.3%
Financial Services
0.5%
Technology
0.5%
Basic Materials
0.4%
Industrials
0.0%
Unknown
1.2%
Sectors come from each company's industry code in its SEC record, so they are coarse. 1.2% of the reported weight could not be placed and is shown as unknown.
Full holdings list, heaviest first
| # | Stock | Weight | Cumulative |
|---|---|---|---|
| 1 | VRTXVertex Pharmaceuticals, Inc. | 8.08% | 8.1% |
| 2 | AMGNAmgen, Inc. | 7.83% | 15.9% |
| 3 | GILDGilead Sciences, Inc. | 6.84% | 22.8% |
| 4 | REGNRegeneron Pharmaceuticals, Inc. | 4.91% | 27.7% |
| 5 | ARGXArgenx SE | 3.76% | 31.4% |
| 6 | ALNYAlnylam Pharmaceuticals, Inc. | 3.12% | 34.5% |
| 7 | NTRANatera, Inc. | 2.89% | 37.4% |
| 8 | RVMDRevolution Medicines, Inc. | 2.78% | 40.2% |
| 9 | BIIBBiogen, Inc. | 2.47% | 42.7% |
| 10 | ILMNIllumina, Inc. | 2.07% | 44.7% |
| 11 | MRNAModerna, Inc. | 1.98% | 46.7% |
| 12 | INSMInsmed, Inc. | 1.78% | 48.5% |
| 13 | ONCBeOne Medicines Ltd. | 1.77% | 50.3% |
| 14 | INCYIncyte Corp. | 1.75% | 52.0% |
| 15 | UTHRUnited Therapeutics Corp. | 1.73% | 53.8% |
| 16 | ROIVRoivant Sciences Ltd. | 1.43% | 55.2% |
| 17 | NBIXNeurocrine Biosciences, Inc. | 1.30% | 56.5% |
| 18 | ASNDAscendis Pharma A/S | 1.29% | 57.8% |
| 19 | GMABGenmab A/S | 1.12% | 58.9% |
| 20 | EXELExelixis, Inc. | 1.03% | 59.9% |
| 21 | IONSIonis Pharmaceuticals, Inc. | 1.00% | 60.9% |
| 22 | BBIOBridgebio Pharma, Inc. | 0.98% | 61.9% |
| 23 | MEDPMedpace Holdings, Inc. | 0.95% | 62.9% |
| 24 | MDGLMadrigal Pharmaceuticals, Inc. | 0.91% | 63.8% |
| 25 | TECHBio-Techne Corp. | 0.86% | 64.6% |
| 26 | BMRNBioMarin Pharmaceutical, Inc. | 0.85% | 65.5% |
| 27 | CRLCharles River Laboratories International, Inc. | 0.84% | 66.3% |
| 28 | ARWRArrowhead Pharmaceuticals, Inc. | 0.84% | 67.2% |
| 29 | AXSMAxsome Therapeutics, Inc. | 0.82% | 68.0% |
| 30 | CYTKCytokinetics, Inc. | 0.79% | 68.8% |
| 31 | KRYSKrystal Biotech, Inc. | 0.75% | 69.5% |
| 32 | HALOHalozyme Therapeutics, Inc. | 0.72% | 70.2% |
| 33 | PRAXPraxis Precision Medicines, Inc. | 0.68% | 70.9% |
| 34 | ABVXAbivax SA | 0.67% | 71.6% |
| 35 | ALKSAlkermes plc | 0.67% | 72.3% |
| 36 | BNTXBioNTech SE | 0.66% | 72.9% |
| 37 | PCVXVaxcyte, Inc. | 0.64% | 73.6% |
| 38 | KYMRKymera Therapeutics, Inc. | 0.64% | 74.2% |
| 39 | APOGEE THERAPEUTICS, INC. | 0.59% | 74.8% |
| 40 | PTGXProtagonist Therapeutics, Inc. | 0.58% | 75.4% |
| 41 | RYTMRhythm Pharmaceuticals, Inc. | 0.57% | 75.9% |
| 42 | RGENRepligen Corp. | 0.57% | 76.5% |
| 43 | SYRESpyre Therapeutics, Inc. | 0.54% | 77.0% |
| 44 | BRKRBruker Corp. | 0.52% | 77.6% |
| 45 | PTCTPTC Therapeutics, Inc. | 0.51% | 78.1% |
| 46 | NUNuvalent, Inc. | 0.50% | 78.6% |
| 47 | TWSTTwist Bioscience Corp. | 0.48% | 79.1% |
| 48 | TEMTempus AI, Inc. | 0.48% | 79.5% |
| 49 | MIRMMirum Pharmaceuticals, Inc. | 0.45% | 80.0% |
| 50 | COGTCogent Biosciences, Inc. | 0.44% | 80.4% |
| 51 | XENEXenon Pharmaceuticals, Inc. | 0.43% | 80.9% |
| 52 | SRRKScholar Rock Holding Corp. | 0.41% | 81.3% |
| 53 | TVTXTravere Therapeutics, Inc. | 0.40% | 81.7% |
| 54 | DFTXDefinium Therapeutics, Inc. | 0.38% | 82.1% |
| 55 | CRSPCRISPR Therapeutics AG | 0.38% | 82.4% |
| 56 | ORKAOruka Therapeutics, Inc. | 0.38% | 82.8% |
| 57 | VCYTVeracyte, Inc. | 0.36% | 83.2% |
| 58 | TXG10X Genomics, Inc. | 0.34% | 83.5% |
| 59 | LEGNLegend Biotech Corp. | 0.33% | 83.8% |
| 60 | ACADACADIA Pharmaceuticals, Inc. | 0.33% | 84.2% |
| 61 | CGONCG oncology, Inc. | 0.32% | 84.5% |
| 62 | DNLIDenali Therapeutics, Inc. | 0.30% | 84.8% |
| 63 | CRINETICS PHARMACEUTICALS, INC. | 0.29% | 85.1% |
| 64 | ERASErasca, Inc. | 0.27% | 85.3% |
| 65 | TNGXTango Therapeutics, Inc. | 0.26% | 85.6% |
| 66 | ADPTAdaptive Biotechnologies Corp. | 0.26% | 85.9% |
| 67 | IBRXImmunityBio, Inc. | 0.26% | 86.1% |
| 68 | BEAMBeam Therapeutics, Inc. | 0.25% | 86.4% |
| 69 | EWTXEdgewise Therapeutics, Inc. | 0.25% | 86.6% |
| 70 | GPCRStructure Therapeutics, Inc. | 0.24% | 86.9% |
| 71 | IMVTImmunovant, Inc. | 0.24% | 87.1% |
| 72 | IDYAIdeaya Biosciences, Inc. | 0.24% | 87.3% |
| 73 | RAREUltragenyx Pharmaceutical, Inc. | 0.23% | 87.6% |
| 74 | DYNDyne Therapeutics, Inc. | 0.23% | 87.8% |
| 75 | ARQTArcutis Biotherapeutics, Inc. | 0.23% | 88.0% |
| 76 | GRALGRAIL, Inc. | 0.21% | 88.2% |
| 77 | NAMSNewamsterdam Pharma Co. NV | 0.21% | 88.5% |
| 78 | RLAYRelay Therapeutics, Inc. | 0.21% | 88.7% |
| 79 | QUREuniQure NV | 0.20% | 88.9% |
| 80 | RCUSArcus Biosciences, Inc. | 0.20% | 89.1% |
| 81 | TARSTarsus Pharmaceuticals, Inc. | 0.20% | 89.3% |
| 82 | VERAVera Therapeutics, Inc. | 0.20% | 89.5% |
| 83 | ELVNEnliven Therapeutics, Inc. | 0.19% | 89.7% |
| 84 | NRIXNurix Therapeutics, Inc. | 0.19% | 89.8% |
| 85 | ALMSAlumis, Inc. | 0.18% | 90.0% |
| 86 | KODKodiak Sciences, Inc. | 0.18% | 90.2% |
| 87 | VCELVericel Corp. | 0.18% | 90.4% |
| 88 | NTLAIntellia Therapeutics, Inc. | 0.17% | 90.5% |
| 89 | CAICaris Life Sciences, Inc. | 0.17% | 90.7% |
| 90 | BCRXBioCryst Pharmaceuticals, Inc. | 0.17% | 90.9% |
| 91 | AGIOAgios Pharmaceuticals, Inc. | 0.16% | 91.0% |
| 92 | IRONDisc Medicine, Inc. | 0.16% | 91.2% |
| 93 | SMMTSummit Therapeutics, Inc. | 0.15% | 91.4% |
| 94 | AUPHAurinia Pharmaceuticals, Inc. | 0.15% | 91.5% |
| 95 | ADMAADMA Biologics, Inc. | 0.15% | 91.7% |
| 96 | BHVNBiohaven Ltd. | 0.15% | 91.8% |
| 97 | ZYMEZymeworks, Inc. | 0.14% | 91.9% |
| 98 | ANABAnaptysBio, Inc. | 0.14% | 92.1% |
| 99 | ABCLAbCellera Biologics, Inc. | 0.14% | 92.2% |
| 100 | SRPTSarepta Therapeutics, Inc. | 0.14% | 92.4% |
| 101 | SNDXSyndax Pharmaceuticals, Inc. | 0.14% | 92.5% |
| 102 | TRVITrevi Therapeutics, Inc. | 0.14% | 92.6% |
| 103 | RXRXRecursion Pharmaceuticals, Inc. | 0.13% | 92.8% |
| 104 | ZLABZai Lab Ltd. | 0.13% | 92.9% |
| 105 | AMLXAmylyx Pharmaceuticals, Inc. | 0.13% | 93.0% |
| 106 | MLYSMineralys Therapeutics, Inc. | 0.13% | 93.2% |
| 107 | FTREFortrea Holdings, Inc. | 0.13% | 93.3% |
| 108 | TSHATaysha Gene Therapies, Inc. | 0.13% | 93.4% |
| 109 | MBXMBX Biosciences, Inc. | 0.13% | 93.6% |
| 110 | STOKStoke Therapeutics, Inc. | 0.13% | 93.7% |
| 111 | IOVAIovance Biotherapeutics, Inc. | 0.13% | 93.8% |
| 112 | NVCRNovocure Ltd. | 0.12% | 93.9% |
| 113 | GRFSGrifols SA | 0.12% | 94.0% |
| 114 | ABSIAbsci Corp. | 0.12% | 94.2% |
| 115 | ATAIBECKLEY, INC. | 0.12% | 94.3% |
| 116 | COMPASS PATHWAYS PLC | 0.12% | 94.4% |
| 117 | URGNUroGen Pharma Ltd. | 0.12% | 94.5% |
| 118 | NVAXNovavax, Inc. | 0.12% | 94.6% |
| 119 | GLUEMonte Rosa Therapeutics, Inc. | 0.11% | 94.7% |
| 120 | TYRATyra Biosciences, Inc. | 0.11% | 94.9% |
| 121 | NUVBNuvation Bio, Inc. | 0.11% | 95.0% |
| 122 | VIRVir Biotechnology, Inc. | 0.11% | 95.1% |
| 123 | IMCRImmunocore Holdings plc | 0.10% | 95.2% |
| 124 | CDNACareDx, Inc. | 0.10% | 95.3% |
| 125 | GHRSGH Research plc | 0.10% | 95.4% |
| 126 | MNKDMannKind Corp. | 0.10% | 95.5% |
| 127 | LKFTLakefront Biotherapeutics NV | 0.10% | 95.6% |
| 128 | RAPPRapport Therapeutics, Inc. | 0.09% | 95.7% |
| 129 | SIONSionna Therapeutics, Inc. | 0.09% | 95.8% |
| 130 | AVBPArriVent Biopharma, Inc. | 0.09% | 95.8% |
| 131 | XNCRXencor, Inc. | 0.09% | 95.9% |
| 132 | BCAXBicara Therapeutics, Inc. | 0.09% | 96.0% |
| 133 | INBXInhibrx Biosciences, Inc. | 0.08% | 96.1% |
| 134 | MAZEMaze Therapeutics, Inc. | 0.08% | 96.2% |
| 135 | PHVSPharvaris NV | 0.08% | 96.3% |
| 136 | WVEWaVe Life Sciences Ltd. | 0.08% | 96.3% |
| 137 | STVNStevanato Group SpA | 0.07% | 96.4% |
| 138 | MESOMesoblast Ltd. | 0.07% | 96.5% |
| 139 | MGTXMeiraGTx Holdings plc | 0.07% | 96.6% |
| 140 | CRVSCorvus Pharmaceuticals, Inc. | 0.07% | 96.6% |
| 141 | KURAKura Oncology, Inc. | 0.07% | 96.7% |
| 142 | SEPNSepterna, Inc. | 0.07% | 96.8% |
| 143 | PGENPrecigen, Inc. | 0.07% | 96.8% |
| 144 | OLMAOlema Pharmaceuticals, Inc. | 0.07% | 96.9% |
| 145 | JANXJanux Therapeutics, Inc. | 0.07% | 97.0% |
| 146 | REPLReplimune Group, Inc. | 0.07% | 97.0% |
| 147 | ZVRAZevra Therapeutics, Inc. | 0.07% | 97.1% |
| 148 | PSNLPersonalis, Inc. | 0.06% | 97.2% |
| 149 | ANROAlto Neuroscience, Inc. | 0.06% | 97.2% |
| 150 | CGEMCullinan Therapeutics, Inc. | 0.06% | 97.3% |
| 151 | THERAVANCE BIOPHARMA, INC. | 0.06% | 97.4% |
| 152 | ANNXAnnexon, Inc. | 0.06% | 97.4% |
| 153 | ZBIOZenas Biopharma, Inc. | 0.06% | 97.5% |
| 154 | GERNGeron Corp. | 0.06% | 97.6% |
| 155 | SLDBSolid Biosciences, Inc. | 0.06% | 97.6% |
| 156 | BIOABioAge Labs, Inc. | 0.06% | 97.7% |
| 157 | ABUSArbutus Biopharma Corp. | 0.06% | 97.7% |
| 158 | CSTLCastle Biosciences, Inc. | 0.05% | 97.8% |
| 159 | RIGLRigel Pharmaceuticals, Inc. | 0.05% | 97.8% |
| 160 | IRWDIronwood Pharmaceuticals, Inc. | 0.05% | 97.9% |
| 161 | ORICORIC Pharmaceuticals, Inc. | 0.05% | 97.9% |
| 162 | SVRASavara, Inc. | 0.05% | 98.0% |
| 163 | MRVIMaravai LifeSciences Holdings, Inc. | 0.05% | 98.1% |
| 164 | SANASana Biotechnology, Inc. | 0.05% | 98.1% |
| 165 | CTMXCytomX Therapeutics, Inc. | 0.05% | 98.1% |
| 166 | FDMT4D Molecular Therapeutics, Inc. | 0.05% | 98.2% |
| 167 | PHATPhathom Pharmaceuticals, Inc. | 0.05% | 98.2% |
| 168 | CADLCandel Therapeutics, Inc. | 0.05% | 98.3% |
| 169 | ACRSAclaris Therapeutics, Inc. | 0.05% | 98.3% |
| 170 | RGNXREGENXBIO, Inc. | 0.04% | 98.4% |
| 171 | OPKOPKO Health, Inc. | 0.04% | 98.4% |
| 172 | ALTAltimmune, Inc. | 0.04% | 98.5% |
| 173 | DSGNDesign Therapeutics, Inc. | 0.04% | 98.5% |
| 174 | ALLOAllogene Therapeutics, Inc. | 0.04% | 98.6% |
| 175 | CTKBCytek Biosciences, Inc. | 0.04% | 98.6% |
| 176 | MYGNMyriad Genetics, Inc. | 0.04% | 98.6% |
| 177 | SPRYARS Pharmaceuticals, Inc. | 0.04% | 98.7% |
| 178 | DNAGinkgo Bioworks Holdings, Inc. | 0.04% | 98.7% |
| 179 | CTNMContineum Therapeutics, Inc. | 0.04% | 98.7% |
| 180 | PACBPacific Biosciences of California, Inc. | 0.04% | 98.8% |
| 181 | CCCCC4 Therapeutics, Inc. | 0.04% | 98.8% |
| 182 | AURAAura Biosciences, Inc. | 0.04% | 98.9% |
| 183 | SGMTSagimet Biosciences, Inc. | 0.04% | 98.9% |
| 184 | ARVNArvinas, Inc. | 0.04% | 98.9% |
| 185 | CABACabaletta Bio, Inc. | 0.03% | 99.0% |
| 186 | PRTAProthena Corp. plc | 0.03% | 99.0% |
| 187 | ALVOAlvotech SA | 0.03% | 99.0% |
| 188 | EBSEmergent BioSolutions, Inc. | 0.03% | 99.1% |
| 189 | ENTAEnanta Pharmaceuticals, Inc. | 0.03% | 99.1% |
| 190 | NGNENeurogene, Inc. | 0.03% | 99.1% |
| 191 | FLGTFulgent Genetics, Inc. | 0.03% | 99.2% |
| 192 | RCKTRocket Pharmaceuticals, Inc. | 0.03% | 99.2% |
| 193 | PRMEPrime Medicine, Inc. | 0.03% | 99.2% |
| 194 | VNDAVanda Pharmaceuticals, Inc. | 0.03% | 99.2% |
| 195 | KYTXKyverna Therapeutics, Inc. | 0.03% | 99.3% |
| 196 | BBOTBridgeBio Oncology Therapeutics, Inc. | 0.03% | 99.3% |
| 197 | AUTLAutolus Therapeutics plc | 0.03% | 99.3% |
| 198 | TECXTectonic Therapeutic, Inc. | 0.03% | 99.3% |
| 199 | EDITEditas Medicine, Inc. | 0.02% | 99.4% |
| 200 | LABStandard BioTools, Inc. | 0.02% | 99.4% |
| 201 | CATXPerspective Therapeutics, Inc. | 0.02% | 99.4% |
| 202 | AVIRAtea Pharmaceuticals, Inc. | 0.02% | 99.4% |
| 203 | OABIOmniAb, Inc. | 0.02% | 99.5% |
| 204 | SLNSilence Therapeutics plc | 0.02% | 99.5% |
| 205 | LXEOLexeo Therapeutics, Inc. | 0.02% | 99.5% |
| 206 | IMRXImmuneering Corp. | 0.02% | 99.5% |
| 207 | UPBUpstream Bio, Inc. | 0.02% | 99.5% |
| 208 | LCTXLineage Cell Therapeutics, Inc. | 0.02% | 99.6% |
| 209 | AVXLAnavex Life Sciences Corp. | 0.02% | 99.6% |
| 210 | FULCFulcrum Therapeutics, Inc. | 0.02% | 99.6% |
| 211 | KROSKeros Therapeutics, Inc. | 0.02% | 99.6% |
| 212 | CDXSCodexis, Inc. | 0.01% | 99.6% |
| 213 | ARCTArcturus Therapeutics Holdings, Inc. | 0.01% | 99.6% |
| 214 | VYGRVoyager Therapeutics, Inc. | 0.01% | 99.6% |
| 215 | QTRXQuanterix Corp. | 0.01% | 99.7% |
| 216 | NOVABRIDGE BIOSCIENCES | 0.01% | 99.7% |
| 217 | HUMAHumacyte, Inc. | 0.01% | 99.7% |
| 218 | LRMRLarimar Therapeutics, Inc. | 0.01% | 99.7% |
| 219 | PYXSPyxis Oncology, Inc. | 0.01% | 99.7% |
| 220 | CRBUCaribou Biosciences, Inc. | 0.01% | 99.7% |
| 221 | TRDAEntrada Therapeutics, Inc. | 0.01% | 99.7% |
| 222 | LENZLENZ Therapeutics, Inc. | 0.01% | 99.7% |
| 223 | TNYATenaya Therapeutics, Inc. | 0.01% | 99.8% |
| 224 | FHTXFoghorn Therapeutics, Inc. | 0.01% | 99.8% |
| 225 | QSIQuantum-Si, Inc. | 0.01% | 99.8% |
| 226 | ACIUAC Immune SA | 0.01% | 99.8% |
| 227 | BCYCBicycle Therapeutics plc | 0.01% | 99.8% |
| 228 | NMRANeumora Therapeutics, Inc. | 0.01% | 99.8% |
| 229 | PEPGPepGen, Inc. | 0.01% | 99.8% |
| 230 | LYELLyell Immunopharma, Inc. | 0.01% | 99.8% |
| 231 | ADCTADC Therapeutics SA | 0.01% | 99.8% |
| 232 | CLLSCellectis SA | 0.01% | 99.8% |
| 233 | BDTXBlack Diamond Therapeutics, Inc. | 0.01% | 99.9% |
| 234 | AARDAardvark Therapeutics, Inc. | 0.01% | 99.9% |
| 235 | TKNOAlpha Teknova, Inc. | <0.01% | 99.9% |
| 236 | MENSJyong Biotech Ltd. | <0.01% | 99.9% |
| 237 | IMMPImmutep Ltd. | <0.01% | 99.9% |
| 238 | GOSSGossamer Bio, Inc. | <0.01% | 99.9% |
Funds that hold the most of the same stocks
The share of IBB that is also in each fund, from the positions both report. Open a fund for its own page, or the overlap figure to compare the two.
| Fund | Overlap | Shared |
|---|---|---|
| XBIState Street(R) SPDR(R) S&P(R) Biotech ETF | 41.6% | 122 |
| LABUDirexion Daily S&P Biotech Bull 3X Shares | 35.5% | 121 |
| VHTVANGUARD HEALTH CARE INDEX FUND | 17.6% | 170 |
| IYHiShares U.S. Healthcare ETF | 16.5% | 32 |
| IWOiShares Russell 2000 Growth ETF | 15.3% | 125 |
| VBKVANGUARD SMALL-CAP GROWTH INDEX FUND | 12.1% | 53 |
| XLVState Street(R) Health Care Select Sector SPDR(R) ETF | 11.1% | 9 |
| IWMiShares Russell 2000 ETF | 10.4% | 169 |
Questions people ask
What are the top holdings of IBB?
Its filing lists 238 stock positions. The largest are VRTX 8.1%, AMGN 7.8%, GILD 6.8%, and the ten largest together are 44.7% of the fund. The full list with weights is on this page.
How many stocks are in IBB?
IBB reports 238 stock positions in its SEC filing of Jun 30, 2026, and together they are 100% of the fund. Cash, futures and bonds the fund holds are not counted.
How do I check whether IBB holds a particular stock?
Search the full list on this page by ticker or company name, for example NVDA or Nvidia. A stock the fund holds shows with its weight and its rank in the fund. If it does not show, the fund did not report it as a position in this filing.
How often do these holdings change?
Funds report their positions to the SEC at each quarter end, and the SEC publishes the filing about 60 days later. Ploutos reads the latest one every week, so the page changes four times a year, and shows the date of the filing it reads.
Why does the coverage not reach 100%?
The list is the stock positions the fund reports. Cash, futures, bonds and other assets the filing carries are not listed, and what the stocks add up to is the coverage shown. A stock fund lands near 100; a fund that holds futures or a cash sleeve lands lower. Weights are of the whole fund.
Compare IBB with another fund·All fund pairs
Descriptive data from public SEC filings. Nothing on this page is a recommendation to buy, sell or hold any fund or stock, and holdings change between filings.